Groups
Company Size (Fulltime employees)
Looking for
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Frederic Bertaina France

Bioxis, creates biomaterial scaffolds that help regenerate tissues, improve patient outcomes, and provide better healthcare opportunities for doctors. We are focused on developing medical devices based on patented biomaterials technology with potentially accelerated pathways to the aesthetic dermatology market.

Our lead medical device candidate MTI-12 is currently at the pre-clinical stage for aesthetic indications; and our hyaluronic acid-based dermal filler brand, CYTOSIAL, has established into exclusive distribution agreements with distributors in Europe and Asia.
Website:
www.bioxis.com
Company Size (Fulltime employees)
11-50
Year of foundation
2010
Looking for
Please specify your partnering goal
Chinese distributor for our Dermal Filler CYTOSIAL
Headquartner in China
No
Plan in China
CFDA completed for CYTOSIAL range of Dermal by Q1 2022.
Medtech Category
Medtech Information 1, Device Name|Description|Development Stage|Licensed Countries
CYTOSIAL|Dermal filler|Market authorization granted|
Medtech Development Stage
Bioxis Pharmaceuticals
CEO 
Functionality
Management

Dr Matthieu CHAREYRE France

Regulaxis SAS is a French biotech company created in 2013 to develop innovative therapies for human clinic based on new synthetic peptides regulating cell growth and differentiation.

Regulaxis is specialized in the regulation of cell proliferation and/or cell differentiation. The potential therapeutic applications covered by our patents are very broad, especially in the areas of joint/bone or nerve cell regeneration, but also in cancer and related metabolic diseases (diabetes, obesity …).
Our mission is to grant licenses of innovative molecules in a pharmaceutical company after completion of phase II clinical proof of concept.

Regulaxis is strategically focused only on high unmet medical needs but has elected as its first priority:
regeneration of articular cartilage using intra-articular injections of its lead candidate REG-O3.

Website:
www.regulaxis.com
Company Size (Fulltime employees)
1-10
Year of foundation
2013
Looking for
Please specify your partnering goal
Investor or licensee
Funding Status
1.1 mEUR (10 mRMB)
Now raising (In USD)
25 mUSD
Headquartner in China
No
Plan in China
Incorporate WFOE as a start to incubate Chinese patent CN109862905A published last 2019 06 07and proceed with Mainland fundraise to sponsor- Finished Pharmaceutical manufacturing operations in China- Engage discussions with Central NMPA to approve our Chinese Clinical Trial designBringing earlier access for Chinese patients to such first therapeutic treatment of OsteoArthritis of the knee,through out licensing to a major Chinese pharmaceutical company
Biotech/Pharma Category
Assets Information 1: Name|Description|Indications|Stage|IP countries
IP registered Mainland China in 2019
Biotech/Pharma Asset Stage
Medtech Category
Medtech Information 1, Device Name|Description|Development Stage|Licensed Countries
First in Class new MoA peptide based DMOAD
Medtech Information 2
NeuroEndocrine Tumors
Target Client Type
Chinese pharma with established market position in OsteoArthritis
Slides Deck
(png, 430.99KB)
Dr Matthieu CHAREYRE
Regulaxis SAS
LinkedIn logo Chief Business Development Officer - Global Pharmaceutical Operations 
Functionality
Business Development

Philippe Fornies France

INOVOTION is a biotech company which offers you a unique in vivo technology dedicated to oncology and immuno-oncology efficacy studies and early toxicity evaluations.
Our Fast, Sensitive, Reliable and Affordable assay will save you time and money, to give you a clear competitive advantage.
This breaking-thought technology, based on chick embryo, provides early analysis of your anti-cancer treatments before the classical preclinical stages. By eliminating low-value molecules early, INOVOTION accelerates your drug discovery process, increases your R&D productivity and reduces its costs.
It’s rapid Go/No Go decision with multi-cancer screening capacities.
This next generation of in vivo efficacy and toxicity tests covers fours main aspects:
- EFFICACY assays for your treatments in oncology and immuno-oncology
- EARLY TOXICITY assays for your drug candidates
- TARGET VALIDATION in oncology
- MULTI-CANCER SCREENING to (re)positioning your treatment
Website:
www.inovotion.com
Company Size (Fulltime employees)
11-50
Year of foundation
2015
Looking for
Headquartner in China
No
Plan in China
At this step, We want to understand the Chinese Market and we are looking for our first Chinese Customers and/or Partners
INOVOTION
Head of Business Development 
Functionality
Business Development

Dr Aixiao LI France

High-content screening for AI-drug discovery
Website:
https://synsight.net/
Looking for
Please specify your partnering goal
fund raising and partners in china
Headquartner in China
No
Biotech/Pharma Category
Dr Aixiao LI
synsight
chinese market business developer 
Functionality
Business Development

Wallace Macindoe France

We are an information-based consulting, integration and IT outsourcing service entity committed to providing premium strategic marketing, financial and operational management solutions for healthcare, pharmaceutical and other life science organisations.
Website:
www.i3consult.com
Company Size (Fulltime employees)
1-10
Year of foundation
2002
Looking for
Funding Status
Non-funding status - Profit based organisation
Headquartner in China
No
Plan in China
The defining characteristic of COVID era pharma and healthcare is the rise of all things digital. A critical mass of companies had been experimenting with digital pilots for some time, some more advanced and larger than others. All saw a significant boost in digital activities during the COVID-19 crisis. This included large scale webinars to engage Key Opinion Leaders (KOLs), disease education programs on a scale not seen before, all-digital new medicine launches, etc. Digital has arrived and is here to stay. Yet, offline has not yet disappeared and will continue to play an essential role. The real answer going forward will be found in the ability of i3 Consult to implement customer engagement hybrid models that build on offline and online activities to offer a true omnichannel engagement model to clients in China. We see the need to develop these opportunities in six (6) niche areas in China: 1) To strengthen retail KA management with distributors and pharmacies in China 2) Enhance commercial capabilities on broad market and retail channel 3) Better patient education to lead trend of prescription outflow from hospitals and retail channels 4) Provide HCP consultation support onsite for professional medical service 5) Improve drug availability through better collaboration and coverage with pharmacies in China 6) Enhance supply chain support by adding cold-chain capability and lower tier market coverage in China
i3 Consult
CEO & Founder